Viking Therapeutics reported a narrower-than-expected Q2 net loss but saw its stock decline due to significantly increased R&D costs, which nearly doubled year-over-year. The company maintains a strong cash position to fund ongoing clinical trials for its obesity drug candidates, VK2735, with key data readouts expected soon.
Viking Therapeutics (VKTX) shares experienced a decline despite reporting a narrower second-quarter loss than anticipated. This negative market reaction appears to be driven by a substantial increase in research and development costs, which nearly doubled to $115.8 million, indicating aggressive investment in its pipeline. While the company's cash reserves remain robust at $502 million, the burn rate is accelerating. This situation presents a short-term challenge for VKTX as investors weigh the increased spending against future potential, but long-term opportunities exist if upcoming data from the VK2735 clinical trials (VANQUISH Phase 3 and maintenance dosing study) are positive, potentially validating the R&D investment. Traders should monitor the upcoming data readouts, particularly for the oral formulation of VK2735, as these could be significant catalysts.